Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for Urinary Incontinence in NDO (CONTENT2)
NCT02660359Phase 3Terminated
- Sponsor
- Ipsen
- Start
- Jul 2016
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
A Phase 3 trial of abobotulinumtoxinA in neurogenic detrusor overactivity (NDO), sponsored by Ipsen. Started Jul 2016; status: terminated.
02
Drugs
abobotulinumtoxinA
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT02660359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02660359.